We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-15.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$3.55B
AUM Growth
-$470M
Cap. Flow
+$314M
Cap. Flow %
8.85%
Top 10 Hldgs %
53.02%
Holding
59
New
5
Increased
5
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$373M
2
GH icon
Guardant Health
GH
+$81.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$21.4M
4
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$20M
5
SEER icon
Seer Inc
SEER
+$18.7M

Top Sells

Rank Stock Value
1
DNA icon
Ginkgo Bioworks
DNA
+$34.1M
2
TWST icon
Twist Bioscience
TWST
+$33.9M
3
EXAS
Exact Sciences
EXAS
+$28.3M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$22.9M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 94.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
26
BeOne Medicines Ltd
ONC
$32.6B
$40.6M 1.15%
150,000
– –
ALLO icon
27
Allogene Therapeutics
ALLO
$635M
$39.5M 1.11%
2,650,000
+550,000
+26% +$9.7M
GBT
28
DELISTED
Global Blood Therapeutics, Inc.
GBT
$38.8M 1.09%
1,325,000
-600,000
-31% -$18.6M
DNA icon
29
Ginkgo Bioworks
DNA
$584M
$36M 1.01%
108,222
-71,848
-40% -$34.1M
ALEC icon
30
Alector
ALEC
$168M
$34.1M 0.96%
1,650,000
– –
ADPT icon
31
Adaptive Biotechnologies
ADPT
$3.68B
$28.1M 0.79%
1,000,000
-440,000
-31% -$13.5M
DMTK
32
DELISTED
DermTech, Inc. Common Stock
DMTK
$27.6M 0.78%
1,745,000
– –
SNCE
33
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$22.4M 0.63%
+90,000
New +$20M
WGS icon
34
GeneDx Holdings
WGS
$2.01B
$22.3M 0.63%
151,515
– –
CRSP icon
35
CRISPR Therapeutics
CRSP
$4.88B
$20.2M 0.57%
266,430
– –
GLUE icon
36
Monte Rosa Therapeutics
GLUE
$1.3B
$19.6M 0.55%
960,882
-1
-0% -$21
SEER icon
37
Seer Inc
SEER
$123M
$18.2M 0.51%
800,000
+650,000
+433% +$18.7M
DNTH icon
38
Dianthus Therapeutics
DNTH
$5.8B
$17.3M 0.49%
243,849
– –
OMIC
39
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$16.7M 0.47%
48,096
-41,666
-46% -$16.2M
EXAI
40
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$14.1M 0.4%
+713,900
New +$15M
ME
41
DELISTED
23andMe Holding Co
ME
$12.3M 0.35%
92,073
– –
FDMT icon
42
4D Molecular Therapeutics
FDMT
$527M
$12.2M 0.34%
555,455
-560,000
-50% -$13.7M
MASS icon
43
908 Devices
MASS
$345M
$10.5M 0.3%
406,502
– –
ZLAB icon
44
Zai Lab
ZLAB
$2.05B
$9.43M 0.27%
150,000
-40,000
-21% -$3.39M
RXRX icon
45
Recursion Pharmaceuticals
RXRX
$1.69B
$9.39M 0.26%
548,156
– –
GBIO
46
DELISTED
Generation Bio
GBIO
$9.38M 0.26%
132,428
– –
ORIC icon
47
Oric Pharmaceuticals
ORIC
$1.1B
$8.84M 0.25%
601,515
– –
KRON
48
DELISTED
Kronos Bio
KRON
$7.93M 0.22%
583,436
– –
DBTX
49
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$5.44M 0.15%
1,170,048
– –
CELL
50
DELISTED
PhenomeX Inc. Common Stock
CELL
$3.64M 0.1%
200,000
– –
1
2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Casdin Capital held 59 positions worth $3.55B, down 12% from $4.02B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Casdin Capital deployed $314M of net new capital in Q4 2021, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was EQRx, Inc. Common Stock: 39,527,669 shares worth $270M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

On the sell side, the largest reduction was Ginkgo Bioworks, an estimated $34.1M trimmed.

  • Casdin Capital's largest Q4 2021 buy was EQRx, Inc. Common Stock: 39,527,669 shares worth $270M.
  • Casdin Capital added most to Sarepta Therapeutics in Q4 2021, an estimated $21.4M increase.
  • Casdin Capital's biggest Q4 2021 reduction was Ginkgo Bioworks, cutting an estimated $34.1M.
  • Casdin Capital fully exited Syndax Pharmaceuticals in Q4 2021, selling an estimated $22.9M.
  • Casdin Capital's ten largest holdings make up 53% of its $3.55B portfolio in Q4 2021.
  • Casdin Capital opened 5 new positions and closed 6 in Q4 2021.
  • Casdin Capital's portfolio value fell 12% quarter-over-quarter to $3.55B.

Based on Casdin Capital's 13F filing for Q4 2021, filed 14 Feb 2022.